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Oral Presentations S165expansion of remaining families of Firmicutes (Table). UponHSCT,
these mice developed fulminant GVHD compared to their counter-
parts who did not receive ampicillin (p\ .01). Interestingly, oral ga-
vage with Lactobacillaceae following ampicillin appears to prevent
exacerbation of GVHD.
Altogether, our results suggest that during GVHD, an increase of
Lactobacillaceae in the gut may be a compensatory mechanism to re-
duce GVHD severity. Moreover, antibiotics prior to HSCT could
predispose to GVHD, while the administration of Lactobacillaceae
can be explored as GVHD prophylaxis.
Table 1. Bacterial family representation in ileal contents
% other
% Lactobacillaceae FirmicutesNormal B6 mice 42±3 26±1
HSCT mice without GVHD 54±2 27±2
HSCT mice with GVHD 95±2 2±0.5
B6 mice after ampicillin and recovery 0±0.1 98±136
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Introduction: The present study attempted to identify potential
predictive SNP marker associating with the risk of acute (aGVHD)
or chronic GVHD (cGVHD) and organ specific GVHDs. In addi-
tion, SNP markers predicting transplant outcomes such as overall
survival (OS), relapse free survival (RFS) or non relapse mortality
(NRM) were also analyzed with 259 SNPs in 54 genes which are po-
tentially involved in the pathogenesis of GVHD.
Materials andMethods: 394 pairs of donors and recipients were in-
cluded and their germline DNA samples were genotype for 259
SNPs in 54 genes using MALDI-TOF based platform. The Risk
of aGVHD/cGVHD and organ specific GVHD were evaluated as
well as RFS, NRM and OS in patients receiving related donor trans-
plantation (n 5 303). After multivariate analyses, the predictive
model generated by combination of clinical and genetic SNP
markers were attmpted to stratify patients into low (\Q1), moderate
(Q2,3) and high risk groups (Q4), which were to be validated in 84
pairs receiving MUD transplantation. Finally, we performed C-sta-
tistic analysis for each transplant outcome in a pooled population (n
5 394).
Results: Several SNP markers in the cytokine, apoptosis, TGF-b or
PDGF mediated pathways were identified as potential predictive of
aGVHD/cGVHD. Of interest,NOS2 (nitric oxide 2) was associated
with the risk of cutaneous or aGVHD. PDGF-mediated pathway
was involved in the pathogenesis of cutaneous GVHD. These pre-
dictive models generated with both clinical and genetic factors
were statistically significant (P\ 0.001) except for overall cGVHD
(p 5 0.07). The genetic predictive models have been replicated in
validation cohort in terms of skin cGVHD (p \ 0.0001), skin
aGVHD (p 5 0.0219), aGVHD (p 5 0.0274), and RFS (p 5
0.0166). The C-statistics have been increased by median of 0.0745
(range 0.023-0.18, mean 0.0788) when adopted the predictive model
generated combined with clinical and genetic factors compared to
that generated only by clinical factors.
Conclusions: The present study suggested that 1) the predictive
models improved stratification of the patients according to their
transplant outcomes and the risk of GVHD (esp. organ specific
GVHD) using donor-/recipient-SNP markers, and 2) the predictive
models incorporating clinical and genetic factors were suggested to
enhance stratification power predicting the prognosis of transplant
patients and the risk of GVHD.37
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Donor HLA mismatching is a known risk factor for morbidity and
mortality after unrelated hematopoietic cell transplantation (HCT).
The frequency of donor and recipient HLA phenotypes differs be-
tween ethnically diverse populations, as does the incidence of acute
graft-versus-host disease (GVHD). Certain high-risk HLA mis-
matches are responsible for acute GVHD risk in the Japanese experi-
ence (Kawase et al Blood 2007). We tested the hypothesis that
clinical outcome after HLA-C mismatched unrelated HCT depends
on the specific mismatch combinations, and that risks are different de-
pending on theHLAphenotypes of the transplant population.The In-
ternational Histocompatibility Working Group dataset enables us to
compare clinical outcome between Caucasian and Japanese popula-
tions to test these hypotheses. High resolution HLA typing was avail-
able for the Japanese (n 5 5986) and Caucasian pairs (n 5 9379).
Multivariable Cox regression models adjusted for HLAmatching sta-
tus other than HLA-C and non-HLA factors known to influence
GVHD risk. In both Japanese and Caucasian recipients, the presence
of an HLA-C mismatch/KIR ligand match was associated with in-
creased risk of grades III-IV acute GVHD compared to an HLA-C
match (HR 1.69 [p \ 0.001] and 1.23 [p \ 0.001], respectively).
KIR2DL ligand mismatching had an even stronger effect among the
Japanese than the Caucasian recipients (HRs for HLA-C allele mis-
match and KIR mismatch in GVH direction were 2.51 (p\ 0.001)
and 1.21 (p5 0.017), respectively). Since it is known that certain mis-
matches that occur in the Japanese population occur very infrequently
(if at all) in theCaucasian population, and vice verse, we conducted the
sameanalysesbut limited to subjectswhohaveHLA-Cmismatchcom-
binations occurring in more than 10 subjects in both populations.
Compared to HLA-Cmatches, HLA-C mismatch/KIR ligand match
and HLA-C mismatch/KIR ligand mismatch were associated with
a statistically significantly increased risk of GVHD in Japanese (HR
1.39 [p5 0.003] andHR3.13 [p\0.001], respectively) but not inCau-
casian recipients (HR 1.18 [p 5 0.128] and HR 0.91 [p 5 0.588]).
These results suggest that the magnitude of risks associated with
HLA-C disparity after unrelated HCT may be different in recipients
of Japanese compared to Caucasian background, particularly in the
presence of a KIR ligandmismatch. Risks may also depend on the spe-
cific HLA-C allele mismatch combinations.
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Introduction: The challenge in RIC HSCT is to prevent GVHD
but maintain GVL and immunologic reconstitution. Bortezomib is
an excellent candidate immunomodulator. In addition to antitumor
activity via NF-kB and other pathways, it inhibits APC by attenuat-
ing TLR-4 mediated activation and cytokine production. In mouse
models, bortezomib preferentially and specifically depletes alloreac-
tive T cells, and prevents GVHD without impairing engraftment or
